Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Anderson-Smits C, Layton JB, Ritchey ME, Hayden V, Chavan S, Souayah N. Patient and treatment characteristics of a large US sample of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) initiating Intravenous Immunoglobulin (IVIG) therapy. Poster presented at the 2020 Muscle Study Group (MSG) Annual Virtual Meeting; September 25, 2020. [abstract] RRNMF Neu J. 2020 Sep; 1(4):61.
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603